Hyperinsulinemia Is Associated With Increased Production Rate of Intestinal Apolipoprotein B-48–Containing Lipoproteins in Humans

• Hélène Duez

  From the Departments of Medicine and Physiology (H.D., K.D.U., R.V., G.F.L.), Division of Endocrinology and Metabolism, University of Toronto, Ontario, Canada; Institut des nutraceutiques et aliments fonctionnels (B.L.), Université Laval, Québec, Canada; and Clinical Research Institute of Montreal (J.S.C.), Canada. Present address for J.S.C.: Heart Research Institute, Nutrition and Metabolism Group, Camperdown, Sydney, NSW 2050, Australia.

• Benoît Lamarche

  From the Departments of Medicine and Physiology (H.D., K.D.U., R.V., G.F.L.), Division of Endocrinology and Metabolism, University of Toronto, Ontario, Canada; Institut des nutraceutiques et aliments fonctionnels (B.L.), Université Laval, Québec, Canada; and Clinical Research Institute of Montreal (J.S.C.), Canada. Present address for J.S.C.: Heart Research Institute, Nutrition and Metabolism Group, Camperdown, Sydney, NSW 2050, Australia.

• Kristine D. Uffelman

  From the Departments of Medicine and Physiology (H.D., K.D.U., R.V., G.F.L.), Division of Endocrinology and Metabolism, University of Toronto, Ontario, Canada; Institut des nutraceutiques et aliments fonctionnels (B.L.), Université Laval, Québec, Canada; and Clinical Research Institute of Montreal (J.S.C.), Canada. Present address for J.S.C.: Heart Research Institute, Nutrition and Metabolism Group, Camperdown, Sydney, NSW 2050, Australia.

• René Valero

  From the Departments of Medicine and Physiology (H.D., K.D.U., R.V., G.F.L.), Division of Endocrinology and Metabolism, University of Toronto, Ontario, Canada; Institut des nutraceutiques et aliments fonctionnels (B.L.), Université Laval, Québec, Canada; and Clinical Research Institute of Montreal (J.S.C.), Canada. Present address for J.S.C.: Heart Research Institute, Nutrition and Metabolism Group, Camperdown, Sydney, NSW 2050, Australia.

• Jeffrey S. Cohn

  From the Departments of Medicine and Physiology (H.D., K.D.U., R.V., G.F.L.), Division of Endocrinology and Metabolism, University of Toronto, Ontario, Canada; Institut des nutraceutiques et aliments fonctionnels (B.L.), Université Laval, Québec, Canada; and Clinical Research Institute of Montreal (J.S.C.), Canada. Present address for J.S.C.: Heart Research Institute, Nutrition and Metabolism Group, Camperdown, Sydney, NSW 2050, Australia.

• Gary F. Lewis

  From the Departments of Medicine and Physiology (H.D., K.D.U., R.V., G.F.L.), Division of Endocrinology and Metabolism, University of Toronto, Ontario, Canada; Institut des nutraceutiques et aliments fonctionnels (B.L.), Université Laval, Québec, Canada; and Clinical Research Institute of Montreal (J.S.C.), Canada. Present address for J.S.C.: Heart Research Institute, Nutrition and Metabolism Group, Camperdown, Sydney, NSW 2050, Australia.

抄録

Objectives— Whereas postprandial hyperlipidemia is a well-described feature of insulin-resistant states and type 2 diabetes, no previous studies have examined intestinal lipoprotein production rates (PRs) in relation to hyperinsulinemia or insulin resistance in humans. Methods and Results— Apolipoprotein B-48 (apoB-48)–containing lipoprotein metabolism was examined in the steady-state fed condition with a 15-hour primed constant infusion of [D3]- l -leucine in 14 nondiabetic men with a broad range of body mass index (BMI) and insulin sensitivity. To examine the relationship between indices of insulin resistance and intestinal lipoprotein PR data were analyzed in 2 ways: by correlation and by comparing apoB-48 PRs in those whose fasting plasma insulin concentrations were above or below the median for the 14 subjects studied (60 pmol/L). ApoB-48 PR was significantly higher in hyperinsulinemic, insulin-resistant subjects (1.73±0.39 versus 0.88±0.13 mg/kg per day; P <0.05) and correlated with fasting plasma insulin concentrations ( r =0.558; P =0.038), despite great heterogeneity in apoB-48 kinetic parameters, particularly among the obese subjects. There was no significant difference in clearance of apoB-48 between the 2 groups, nor was there a significant correlation between apoB-48 fractional clearance rate and fasting insulin or homeostasis model assessment-insulin resistance. Conclusions— These are the first human data to conclusively demonstrate that intestinal apoB-48–containing triglyceride-rich lipoprotein PR is increased in hyperinsulinemic, insulin-resistant humans. Intestinal lipoprotein particle overproduction is a newly described feature of insulin resistance in humans.

収録刊行物

• Arteriosclerosis, Thrombosis, and Vascular Biology

  Arteriosclerosis, Thrombosis, and Vascular Biology 26 (6), 1357-1363, 2006-06

  Ovid Technologies (Wolters Kluwer Health)

キーワード

• Cardiology and Cardiovascular Medicine

詳細情報

• CRID: 1363951795967562752
• NII論文ID: 30023095514
• DOI: 10.1161/01.atv.0000222015.76038.14
• ISSN: 15244636
• ISSN: 10795642
• Web Site: https://www.ahajournals.org/doi/full/10.1161/01.ATV.0000222015.76038.14
• データソース種別:
  • Crossref
  • CiNii Articles